Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, B. Davis, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, et al.
N Engl J Med, 343 (2000), pp. 1520-1528
[2.]
F.T. Ruschitzka.
Clinical trial repert. The APPROVe Study: What we should learn from the VIOXX withdrawal.
Curr Hypertens Rep, 7 (2005), pp. 41-43
[3.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whel ton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long.term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[4.]
C.P. Cannon, S.P. Curtis, A. Fitzgerald, H. Krum, A. Kaur, J.A. Bolognese, et al.
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Artrhritis longterm (MEDAL) programme: a randomized comparison.
Lancet, 368 (2006), pp. 1771-1781
[5.]
J. Martínez González, J. Badimón.
Mechanism underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Current Phram Des, 13 (2007), pp. 2215-2227
[6.]
D.J. Graham, D. Campen, R. Hui, M. Spence, C. Cheetam, G. Levy, et al.
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs:nested case control study.
Lancet, 365 (2005), pp. 475-481
[7.]
L. Laine, S.E. Maller, C. Yu, H. Quan, T. Simon.
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Gastroenterology, 127 (2004), pp. 395-402
[8.]
L.A. García Rodríguez, L. Barreales Tolosa.
Risk of upper Gastrointestinal Complications Among Users of Traditional NSAIDs and COXIBs in the General Population.
Gastroenterology, 132 (2007), pp. 498-506
[9.]
A. Lanas, L.A. García Rodríguez, M.T. Arroyo, F. Gomollón, F. Feu, A. González-Pérez, et al.
Gut, 55 (2006), pp. 1731-1738
[10.]
V. Stand.
Are COX-2 inhibitors preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?.
Lancet, 370 (2007), pp. 2138-2151
[11.]
F. Castella-Lawson, M.P. Reilly, S.C. Kapoor, A.J. Cucchiara, S. Demarco, B. Tournier, et al.
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
N Engl J Med, 345 (2001), pp. 1809-1817
[12.]
J. Ellison, W. Danger.
Recent FDA warning of the concomitant use of aspirin and ibuprofen and the effects on platelet aggregation.
Prev Cardiol, 10 (2007), pp. 61-63
[13.]
Lanas Arbeloa A, Bajador Andreu E. Gastroenteropatia por AINE. En Julio Ponce Ed Tratamiento de las Enfermedades Gastroenterológicas. 2.ª ed. Asociación Española de Gastroenterología. Madrid: SCM S.L.; 2006. p. 121-7.
[14.]
D.Y. Graham, N.M. Agrawal, D.R. Campbell, M.M. Haber, C. Collis, N.L. Lukasik, et al.
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs Lansoprazole.
Arch Intern Med, 162 (2002), pp. 169-175
[15.]
J. Regula, E. Butruk, C.P. Dekkers, S.Y. de Boer, D. Raps, L. Simon, et al.
Prevention of NSAID associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole.
Am J Gastroenterol, 101 (2006), pp. 1474-1755
[16.]
J.M. Scheiman, N.D. Yeomans, N.J. Talley, N. Vakil, F.K. Chan, Z. Tulasasay, et al.
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors.
Am J Gastroenterol, 101 (2006), pp. 701-710
Copyright © 2008. Elsevier España S.L.. Todos los derechos reservados
